Friday 6 November 2026 Export BMRN’s income statement to Excel — free account

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.

Revenue: +32.0%
EPS: −296.6%
Free cash flow: −52.3%
Total debt: +599.5%

Quarter to September 2026, against a year earlier

Revenue growth 3 yrs

55.89 0.23 −0.41%

Follow BMRN

Alert me

Market cap: $10.9B
P/E: 0.0×
Fwd P/E: 32.7×
Dividend yield: —
F-score: 5/9
Altman Z: 5.67
Beneish M: −2.49
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

BioMarin Pharmaceutical Inc. 10-K filed Feb 26, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed Feb 26, 2026 · accepted 12:30 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 7, Management’s Discussion and Analysis, against the 10-K filed Feb 24, 2025: 20 added · 10 removed · 27 modified; 7 with only figures updated; 1 moved without change

BioMarin Pharmaceutical Inc. 10-K filed Feb 26, 2026

What changed

Stockrow Weekly